Charles River sees Q1 EPS growth in high-single-digits, consensus 49c
Sees Q1 revenue growth above 20%, consensus $595.15M. Guidance does not include the impact of proposed Citoxlab acquisition. Says FY18 performance was driven by robust industry fundamentals. Says worked on 85% of approved drugs in 2018. Says pace of demand for essential products and services accelerated during the second half, positioning the company extremely well for 2019. Says the company expects Citoxlab's shareholders will enter into a definitive purchase agreement upon completion of the labor consultations. Says investments to support growth and enhance scientific capabilities, including the proposed acquisition of Citoxlab, position the company extremely well to capitalize on new business opportunities in 2019. Guidance and comments taken from slide presentation ahead of Q4 earnings conference call.